ingenol mebutate sold brand name picato substance found sap plant euphorbia commonly known petty spurge inducer cell death compound isolated first plant gel formulation drug approved us food drug administration european medicines agency topical treatment actinic keratosis two different strengths gel approved use either face scalp trunk extremities drug withdrawn market irritation application site common various types irritation include redness scaling crusting pain severe itching sometimes infection additional possible side effects include eye irritation periorbital edema patients studies headaches nasopharyngitis running nose allergic reactions shingles changes pigmentation application site chemical conjunctivitis corneal burns may also european medicines agency recommended suspending marketing authorisation ingenol mebutate due concerns regarding increased incidence skin cancer patients treated topical ingenol mebutate compared vehicle imiquimod physicians advised refrain prescribing ingenol use different treatment subsequently marketing authorization holder requested withdrawal manufacturing authorization commercial reasons withdrawal granted therefore ingenol mebutate longer registered ingenol mebutate effectively absorbed skin bloodstream interactions oral drugs substance ester diterpene ingenol angelic acid semisynthesis ingenol mebutate starting ingenol described chemical research group denmark synthesis ingenol relatively inexpensive constituent turpentine published july mechanism ingenol mebutate causes cell death still fully understood one study squamous cell carcinoma precursor actinic keratosis cultures found pkcmekerk signaling pathway involved causing cell death treatment ingenol mebutate addition interleukin decoy receptors induced resulting reduction longterm viability cells could help prevent results four multicenter randomized doubleblind studies shown ingenol mebutate gel applied topically trunk days face scalp effective field treatment actinic twelvemonth followup study performed actinic keratosis patients treated ingenol mebutate treated face scalp trunk extremities study found treated face scalp sustained clearance treated trunk sustained clearance period ingenol mebutate also found useful reactivating latent hiv virus cells taken individuals tested negative signs disease following extended courses antiretroviral drugs raising possibility drug may used expose last traces virus thus potentially provide permanent cure hiv infection research ongoing determine whether effects observed vitro also seen animal models view eventual human trials placebocontrolled study hairless mice found ingenol mebutate gel able remove twoweekold tattoos consistently observed microspheres within skin containing dye would exude scab intact slough skin healed days treatment began mechanism appears independent ink color unlike laser tattoo removal less effective certain colors reports human trials health canada assessed twelve studies published scientific medical literature order determine link use ingenol mebutate skin cancer health canadas review found six twelve studies evidence skin cancer use ingenol mebutate european medicines agency ema also reviewed safety issue april concluded ingenol mebutate may increase risk skin cancer risks outweigh benefits february manufacturer voluntarily withdrew product european union httpsenwikipediaorgwikiingenolmebutate